Clinical Study
CABL001I12201: A Study Drug for Children with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
Philadelphia chromosome-positive chronic myeloid leukemia is a disease that causes abnormal changes to the chromosomes leading to high levels of abnormal cells in the bone marrow and blood. CABL001I12201 is a study drug for children with this disease. Research is needed to learn the safety and effectiveness of the study drug. The information we gain may aid future patients.
For more information contact:
Maydeen Ogara
maydeen.ogara@hsc.utah.edu
801-587-3579
IRB#: IRB_00158588
| PI: Mallorie Heneghan
| Department: PEDIATRICS
| Approval Date: 2023-04-05 06:00:00
Specialties: Pediatric Hematology & Oncology
Who can participate?
Gender: All
Age: Under 18 years old
Volunteers: Volunteers with special conditions
Location: In Person
Inclusion Criteria:
- Ages 1 to 18 years old
- Specific levels of bone marrow and blood counts at the first study visit
- Prior treatment with a minimum of one Tyrosine kinase inhibitor (TKI)
- Prior treatment with a minimum of one Tyrosine kinase inhibitor (TKI)
- Attend a University of Utah
Exclusion Criteria:
- Current or history of specific heart diseases
- Planning to have allogeneic hematopoietic stem cell transplantation
- Previous treatment with hematopoietic stem-cell transplantation.
Will I be paid for my time?
Yes